BWXT - Earnings call transcript Q4 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, welcome to BWX Technologies Inc. Fourth Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. [Operator Instructions] Following the company's prepared remarks, we will conduct a question-and-answer session and instructions will be given at that time. Please note this event is being recorded. to BWXT’s call Relations. Vice like host, to now Kratz, Mark President would turn over the our I of Investor go ahead. Please

Mark Kratz

quarter Thank to earnings evening Good and fourth call. you, XXXX full and year Andrea. BWXT’s welcome

of me that Robb Senior and the is today’s we available Vice and fourth the sector On LeMasters, will CFO. on are reference Rex BWXT and quarter Joining President call, CEO website. Geveden, President earnings Investor presentation

involve Investor statements and that Harbor constitute our We those forward-looking in uncertainties SEC will also certain described These including discuss provision matters statements. found materials filings. risks the Safe in the and

you. frequently discussed will that reconciled materials. which are With to to GAAP Rex, I We the financial in turn those non-GAAP measures will measures over call

Rex Geveden

everyone. Thank good Mark and evening you,

for I for at welcome has Robb appetite the impressed a Investor LeMasters stewardship company's you met all his BWXT's Before Robb Robb new his call role for into Officer. improvement, few Chief ago, his and with and first financial many Financial we his our the his assuming get want him the to to of earnings as when Day continuous us months disciplined of his new results, me was role, drive detail, of Since time. resources. first to

cost managing of within asked through expanding CapEx including improving the As I've angles XXXX, focus to Robb capital, financial managed efficiencies and a for capital the multi-year and from company. maintenance working and rolls driving several future the on path off in company accelerating glide campaign and growth, efficiency synergies downward margins levels results itself our the positions on

and increase support make how to investments modernize will can we operational assess small We operational future functions. also effectiveness

our two is positioned from the large on and vectors. execution, our layer streamlined campaigns BWXT focus margin to in firmly expansion revenue growth capital completion in new near-term of With

be segments two. segment called Commercial Operations. segments we to path lines within first This consolidating Our intend Government operating structure new how new to meet step from and is The capabilities with customers' three organizational will leverage into on that effectively needs. nicely Operations more up each

expect shareholders. customers also this synergies to in our our and both cost meaningful future for We strategic action result and

Turning now fourth strong growth otherwise We an on per quarter we million results, of in year. wrapping on earnings earlier representing note today, of earnings modest XXXX to reported a finished XXXX. of $X.XX, share earnings revenue, with up XXXX $XXX solid challenging from $X.XX

give on on saw challenges across you let business BWXT. making So, color update we're the exciting what progress some we me providing a before

foremost, and saw the to First quarters. that pandemic had COVID-XX some We efficiencies in and the persisted. the third the occurred the in earlier forfeited during that year. fourth to expected first gain we back had impacts operating in the We heaviest quarter spikes productivity

Omicron of the However, progress limited variant once rapid spread unforeseen again. the

operating We XXXX, are of full believe we we continue COVID. then It's on to the experience income to lingering components. of across business site was necessarily estimate to coordinating within we concentrated pressure our on our is critical were these things but financial turning but of million north majority easing disruption corner of year finally into well it define the disruptions, impact hard was workforce $XX manufacture the specifically that early and where and

large operating into related timing awards proving was by COVID-related the disruptions. of aggressive. of call. business new was Navy by hindsight, services And be in conservative and customers, As the government transportation in delayed even machinery complex exacerbated our from and major estimates chain supply factories, to I which itself other challenge growth installation to last from mentioned on the the major complications came the workflow

runs through of an operational achieve modestly had we some roll-off headwinds, fast the in income. grow reimbursement, beginning and to all operating cash otherwise remain XXXX themselves expressed and challenges, earnings, to Navy executing last our important segment of years milestones namely We which Despite business, earnings of come. campaign. the in able financial operational In developmental we major the and and Beyond entering we advancing that the challenging cash initiatives focused robust the year. in headwinds were the growth on in capital pension backlog against and core our our are year

with shipbuilding that So, greater reporting XXXX next the cost meet upgrading capacity decades. the production to and commensurate the Impressively, in should our over facilities to our flagship to equipment budget, CapEx experienced our resulting in installation the and the forecasts are abate. we capacity. scheduling plan with Navy provide growth visibility business systems XXXX should begin and the we leave few bottlenecks With equipment investment necessary our

that update also organically believe domestic of demand should global their Navy and additional Task of an the systems potential partnerships. in as Ocas Nuclear-powered from XX-month we surface of by the and landscape, if of the On from needs note, to needs that shoehorn Force, our We an stand into some that planning on able contentious to we and or capacity. U.S. light increasingly be perform an continue assessment enhanced our workload Submarine as allies they [ph]

to could the don't we and we in the capacity security a any performing support capabilities are partnerships. to update roles offer on for and engage that self-evaluation on our our specific Navy While company, potential parallel, continue have we customer

over Navy running to the transition and for ago, license design Administration year and ahead purification. the to scale Security and the production or Beyond two. uranium leveraging of the and conversion a we work, schedule from to Nuclear a business. awarded to our that next prototype process contract grow I'm is BWXT pleased About demonstration well was report to National look year we are a one project system the category

another BWXT's the and we XXXX. in all project Mission the XXXX solid to long-term contract government this on proceed transition currently Shortly and for anticipate services business On contract We provide over Savannah Savannah the of a of River activity Energy began fee-bearing the competitor. deliverable after the Department in Integrated Pantex venture Y-XX the Award, spring and the to side, to authority is and Cleanup received are expected joint satisfying River course the M&O growth awarded EBITDA requirements.

However, protested the Ultimately, has the about award and remain corrective of proposal paused and the BWXT Energy. optimistic DoE was actions. competitive await team's determination the the we Department subsequently pending from award will a

schedule it review we've year. Lastly, life progress progress of duration in the are demonstration more that Operations, the will phase. the We make we be Commercial the completed We extension Capabilities continue in and receipt Operations, recently, RFP around and another programs. for Government to multiple now In long continue middle we for to on on Office, Strategic of anticipate micro-reactor the awarded Power chain around projects seen deploy licensed Generation build. opportunities. the to to grid Ontario-based the SMR of modular solution strength as early XXXX. to of December, selected as supply In inclusive They reactor intend positive Canada's the developments nuclear Ontario the GE construct is at Darlington nuclear first commercial Hitachi the leverage long-term site, new already for BWXT scale small which SMR design early

As after Poland announced as XX energy deploying GE, Green on component are and more nuclear the leverage BWXT, a decarbonize, the in OPG the key renewed Shortly reactor we the pressure modular small Energy power The in Hitachi, interest nuclear Tennessee GE, construction manufacture seeing Synthos unique Hitachi, reactors, starting skilled internals, exploring SMR. and also provinces announcement, -- projects vessels, portfolios. to reactors of to green facilities is by we with multiple intention workforce, range early and suited cooperate nations products, well other a Authority advanced of its including intends to components. the wide are BWXT Valley and which of reactor XXXXs.

facility used I from the Tc-XX a All a package. production be our our standards for efforts which acceptance the to The utilize at month. We FDA quarter. drug operationally widely of to installed have FDA the support successfully will the cold fourth XXX the equipment we clear update We end from remain We to the to FDA. batches Tc-XX. runs path for used as quarter are batches methods, cold kits validate being most produced into complete the chemistry input have with market -- for and Lastly, that in control are is with scale of pharmacopoeia also substance will that and the needs America, label a critical submission repetitive completed ready. our generator [ph] All hot our confident the package Tc-XX results data the and given full new modifications on product are these meets commercial see drug you such this been Curie and for those data the North integrated the product to the a generator positive regulatory in quality chemistry line and we want commissioned. application provide the detailed by commercialization BWXT

pleased type formal the feedback FDA agreed B priority. strengthening a a a supply high with We few held FDA drive Mo-XX are meeting remains weeks that were The the with also to shaping package submission. a We chain the our quality and ago.

To to two The submission the reactor XX% that intend the over Mo-XX. in to we request the fact, full months, of has fragility shutdown our world's FDA. end, last of this In priority with on with been review the a display supplies Netherlands HFR the that

is attractive of be continuity targets a reminder, feature in highly a that power our meaning product uses reactor As BWXT that irradiated ultimately Ontario, will supply offering. the in of a

to prior the FDA testing coming will of pharmacy weeks, left submission, complete line. what in So, the is we radio

through and validation the and but chemistry entails Following of high manufacturing, We yielding major using full cold exciting drug required only generator three therapeutics phase. the and sequence. is by medicine a through some through complete batches material process, will publicly. to production testing disclosed committed registration quality nuclear which of partnerships, the in we which the our that three also market to hot of the this contract This not Tc-XX for data line, growth tests we remain build qualification through last the Final conduct have component enabled entire FDA expansion data package. into expect rounds hot multiple

consisting Rob. nuclear uniquely with multiple investors, that, commercial energy compelling and for turn shots assets, And believe clean provides markets. to our with this adjacent growth, on that let the with we portfolio power core Finally, predictability defense defense and over of in high positioned me combined call goal optionality our nuclear and businesses

Robb LeMasters

agree team I I do of and can and Thanks to an everyone. there support taking we under around challenge growth interesting as positioning evening fruit good after Rex investments thanks Rex's me. that these excellent leadership. to as bear we with forward honing for prepare strategic look markets much for years of on

resulted offset $XXX operations start last $XXX quarter quarter increasing revenue in fourth driven about segment, higher nuclear Let's year, slide quarter robust strong points This operations earnings revenue. full slightly was margins company and both year, by million, power their nuclear nuclear by XXX of at lower margins XX% Fourth for million, adjusted by in with billion was nuclear driven up four revenue NOG in at EBITDA and the EBITDA the segment up at the higher basis Fourth XXXX, $X.X with compared NPG. in on power presentation. operating total the results with both quarter and fourth X% segments. power depreciation stronger than also nuclear was growth

the X% also million. adjusted was headwind of of to result For year, million full $XX.X pension EBITDA included down EBITDA. or net X% This FAS/CAS $XXX

down and watermark despite -- in year. high when the we driven year the compared to earnings had tax significant corresponding delays. lower the $X.XX earnings were our benefited results $X.XX related the of reimbursement XXXX that So, negative with Fourth for and as of Full in that XX% would a from up share challenges rate quarter these a compared challenges and award State impact part per were the well reimbursed a reversal. a some to tax earnings increase in and faced NOG would COVID-XX considered the note taxes government fourth been this quarter share, with required are share, change $X.XX have operating base modest a year. cost XXXX government costs, include per was prior I business X% Again, a throughout income. by company fourth as businesses a underlying step state that quarter contracts XXXX. of multiple up last EBITDA year per pension

the all a takes. puts on have slide XXXX to five bridge and provide of detailed We EPS

Nuclear and operating lead In segment up margin Let of me XXXX six revenue, quickly into year field quarter, X% significantly million, from seven, fuel results service Nuclear was higher sales, on full handling BWXT Power commercial XX.X%. the the reported Operating and higher more was the quarter. fuel side. segmentation. through up were Group, revenue was and are activity driven old higher more driven NOG slide sales operating up XX%. labor by on Revenues step higher generated $XXX $XX which mix. benefited was volume power and $XXX a Medical quarter fourth also In million X% fourth by the robust the higher and $XX.X revenue income up material favorable Segment were long a XX.X% for and production. X% margins million and driven Segment which million, income up also XX.X Operations by

Nuclear operating contract quarter. million down in income costs the Lastly, fees $X.X was higher fourth Services' lower and million to some $X.X on

down service productivity inefficiencies that efforts unable came as up XX%. business. in a on we and that For power year. X%, year by income, Medical up handling from the finished and segment income a driver processing impacted fuel from also by was performance But was down field higher additional persistent our throughout incremental installation contract lower volume fuel were release. NPG's on fees revenue was was slightly also more hire Operating $XX.X this lead higher COVID-related Nuclear million driven higher year's less production. margins and commercial sales that year, income. the labor this business to absences overall and the full were about and XX% revenue government overtime finished long material year by finally, capital primarily best Nuclear revenue year labor. XX.X%, on less NOG to negatively at compressed more and FAS/CAS was work primarily than performance. year operating with to equipment last BWXT XX% offset as the operating margins little than COVID increased than Power the was Services by Operating activity down better X% uranium despite And income was overcome bottlenecks driven

like the that I turning would to spend of on Rex Before a minute earlier. guidance, to spoke RE segmentation

can NOG Operations slide new the you is to segments combining legacy segments. the on see Commercial Operations into As we new segment. eight, the are NSG and Legacy NPG moving Government

costs. to eliminating pre-commercialization the held new well as other activity Tc-XX are Those which as moved a will basis. respective R&D legacy We segments their costs project-by-project segments on be

at spend run year our our having a about in You up. investment at the that as that Tech-XX in will P&L recall was been million Day Investor $XX little pre-commercialization And expectation we outlined that would XXXX higher per running effort of stood it XXXX. before is fully

reporting full unification found the a business' of were efficiencies. step logical the core And cost to are evaluate our of report manage, making vectors will So, next to performance. continue and growth But get these we to new and a operational emerge, The optimize, picture those businesses. reasons main how expect some this as costs commercial was financial re-segmentation we in for opportunities. two

capabilities under managed decision-making. seamlessly. will provide will unification of and NOG and and NSG personnel of First, one grows, transfer to cohesive more training roof need The as the business services our technical cross be

Second, efforts costs new micro advanced larger the begin and as facilities Operations Real the already this parts of seem fuel in they and our possible other become to can lines, benefit Government business present reactor family. structure. supporting synergies highly with from

expectations XXXX, early closely of establish Moving guidance the EBITDA slide reporting to and term EBITDA nine, with our annual aligns today's for which in medium guidance that addition the guidance segments. we on XXXX ranges includes growth

affect the operations included are as this reporting have first transition guidance the guidance. providing XXXX. We segments quarter Note that also cash we in on new of from we

this EBITDA total year. we company and about X% revenue to we of our Day, see out growth at As laid X% Investor

variability our anticipate to reiterating $X.XX. million EPS We to of we $X.XX about the million range We the $XXX in of more single-digit and we range the segments, range million. of representing anticipate million operating are $XXX a In In cash X% grow of revenue Operations expect million flow a Operations, $XXX X% in expenditures to be expected to see to EBITDA the capital Commercial medical XXXX to $XXX with business X% of $XXX revenue upside $XXX million, X% Government our to around to is of growth. business. growth, and range high

line, in $XX million product the commercializing Operations Tc-XX EBITDA continued Given $XX to million. to is be Commercial investment expected

business page influencing on to provided want cadence expectations. also year, see of prior dissimilar have the the I to to We earning years. number provide support other color large, shape There information items are not XXXX this shaping on this a the how but up we modeling by and of some are year. that for

this pressures what of to and core gains are year variant mention others and business. in this its in spike. industry, absences with and Rex itself as others with efficiency manifested some early COVID-related line Omicron an in get we -- productivity the impact seeing are our labor inability see the from First, Most Navy

regular conduct low minor fall, medical where and in So, XXXX to, field we cycle the a award profile. which the sharp, strongly in expect as and and and not typical in of earnings this in be have Since earnings work, that some products. Operations which as the coming quarter earnings up middle to increased In planned of year, higher have of XX, All slide a quarter the made we Investor fourth range Operations, similar the components occurring due awards. guidance the to originally a this service River the in XXXX, fee we annual in part the quarter. we business is $X.XX On fourth first for for the when some through potential to of cyclotron in first stepping isotopes we first XXXX true-ups. said, XX% we the fourth first is core see our In but to quarter spring generate operations, part guidance the segment, around is quarter, services on was little some about the a quarter, second of Savannah bridge. typically maintenance in finishing depressed predicated expected of and profit, driving we our transition quarter Government Day, of updates the In outsized Commercial also to outage slide. we provided have non-fee-bearing activity growth a the $X.XX on provided expect large large

$X.XX, service we to successfully that given $X.XX to on transition the River end range lower on contract. that raised have that revised have give awards. range the of update an We We begun contract Savannah

end are we saw high the ultimately range rates in been delayed we million that has that of pulled resulting DoE in result with in transition. corrective been lowering a by count. lower in offset the net However, to expect the share Y-XX line businesses headwind of below a XXXX. a generally modest are Pantex the which those no items, Besides action, largely There's headwinds, line interest pension, Other how given are change in include back FAS/CAS contract for $XX and the tax it expense, adjustments November.

remarks enough Lastly, some M&A. and at I fallen over acquisition criteria. meeting for leading a many have close a look of taken with but our several function that strategic of on half, financial to a Since short targets, wrap-up want have I and year

in and and continue disciplined businesses. our Clean our remain Energy approach Government prefer to strongly small tuck-ins will to core We

we about portfolio best think of as the shareholder optimize and current unemotionally side M&A, to we evaluate the value. other the On continuously ways

evaluate can and through materializes, at will as that we process have do share time. at our change, growth value price We alternatives. value new separation iterative circumstances believe we that looked manifest the or an this is suitable anything not shareholder see the businesses unlocked it and would in will While

let I'm drive me eager been all explore our let exciting of advancements create say which Mark. we to meaningful just growth unique plan through that that, back will I technologies, to businesses it Now, long-term me believe expand pause this solid prospects. to BWXT's underpinning that the of help time. vectors, to With financials, durable part be in opportunity company and the new new value With hand over and have we've very and to growth

Mark Kratz

Thanks That and ahead concludes go Operator, open remarks. please questions. today's Rob. line for prepared the

Operator

Please begin now first our will Ciarmoli And session. go question-and-answer Truist. We from [Operator ahead. Michael will the Instructions] of question come

Michael Ciarmoli

guess taking then basically afternoon, the remind for -- in included you us good or whether of can that that guys. billion, as the $X.X it here. can work and of Hey, historically of booking, range in was what's the a quarter Thanks Maybe, the Rex had sort to other here? And sort questions there? costs, just Robb, -- input either against you you part future bookings sort for contemplated NOG I for of same costs get on inflation raw expect material you what of margins hedging X. was

Rex Geveden

and -- me let way. the Michael, by Yes, good afternoon,

for agreement, an as maybe to on a Let Virginia's me one, that over, was order you the was and bit little That inflation start with which, that an prior it flip the that aspects. Robb pricing related four Columbia. materials had know

so Virginia growth nuclear a out coming is that really a this the and on And booking funding in what a continuing of operations course, have was -- it’s was. just funding that Columbia year so of some program, we feathering with

Michael Ciarmoli

Okay.

Rex Geveden

of that government protect, Maybe And inflation protect hedge the In use agreements, sort you Robb, terms suppliers. those extent labor I build structure for flavor. against, our we think, know, quotes you some pricing could against to materials agreement with and from we plan of some of in and in by escalation our to what add firm some we how extent, customer. pricing

Robb LeMasters

sure. Yes,

what's we're pricing. supply you side, of material on as the On terms are monitoring raw all going in

agreements, is As have on very know, to going years. pricing out over multiple schedule play generally we sign we that up how good visibility these

pricing these We the of sizing three have of almost when materials we're sort agreements. up known quarters

to sort quarter. that we're on extent, of remaining then some So, exposed

were monitoring we that. constantly So,

have next try into some make we're adequately. to the sure the see that to course, monitor of agreement protected sort that time. that of And door out can, and of bake and of as then subsequent our we much agreements pricing line, pricing in if we we'll in actually we escalation try escalation to agreements, over as that as we We sign get gets

Michael Ciarmoli

And gears Got I submission the it. submission just roadmap probably Got laid at is seemingly, That Investor the it. more to detailed guys FDA of out here. the but makes I sense. you slipped shifting on know then Day, Tc-XX, a guess the

call seemingly think a we But the I laid and of mean, track? Or have of kind sort of everything chunk. of XX by I of ramp good on said, create any -- will should kind that a delay of or out slipped he end last this still of you sort plan year? it assume threw any first day headwinds there commercialization terms on quarter, that that you kind out in

Rex Geveden

Where said the I really little Michael. feel that we're facility deliberately issue. a submit my was now, ago, completely to I done. and done we right having tax of is at doing in are about the there script been we hedging radio And it integration here, because then COVID done. expect the end and A completely would are Italy No, bit stands quarters issues chem testing from because in is as getting good over we were of the modifications farm around time, completely particular, radio that all and it software runs and and testing experiencing language, COVID things few said, some trouble year, were we've doing where we in by in I hot I supplier

it cold to running hot through that ready factory we're tagging go kits. So, and product this have to gleaming product we

and progress well more. and see and very the little I'm pleased and, between even very FDA with submission schedule the so And now risk

risk the So position. no risk more the here. and as maintain there's great going a importantly, It's to this very We've I see finish for and just technology line. that we're product product about industrialization It's the technological market the I always really no close really, suggested be about quality. the that to of

Michael Ciarmoli

Got jump queue. I'll lot in the back Thanks a it. guys.

Rex Geveden

Thanks Mike.

Operator

of Bob go CJS Securities. Please question next Our ahead. comes from Labick

Bob Labick

Good my afternoon. Thanks taking for questions.

Rex Geveden

Bob. Hey

Bob Labick

the I timeline. the pick excited really running on We're on hear -- I about chemistry of thanks. on and last hot want comments wanted to up stuff. submission the kind that just to FDA to

that review you So, that FDA could NIM mentioned from confidence you And priority incremental what big what seeking is these you And don't the seeking FDA, submitting? how submission questions It's rare of remind a kind seeking what opportunity, they're what out? in as and for time, the given you're insights this and of to then right? for but obviously, have things means? event. plays what you're all a happen what us gives the it It's you timeline the kind

Rex Geveden

sure. Yes,

on progress that, So, had say I'd there's to FDA The meetings is of one of we've couple with series on update a answers the a approach. to Bob. them our and our

So, they have meeting through script. visibility go all along development, to B type this this including the referred in as we I that

and doing, know And so we're what are. know their they what we expectations

So, that's one aspect of it.

all consultants in perspective, dimensions radiopharmaceutical that standards. decades FDA for The approval know own is that medical One aspect that Maybe it the the devices there's the other involved been -- of the looking we of FDA what the to experience of sort some team. have couple have are of the a who second must have and to a from it there's this. on we exactly out that and parameters course, satisfy for control meet quality published pharmacopoeia a this our for, is point has that drug there, to final FDA

we have on And the have And we this the the dialogue experts itself. inside. running experts so FDA on the outside, have pharmacopoeia, with we

response what they to I that submit. an timeline going about side on additional hoping And be get not front think letter FDA the on of of complete the we complete very something range certainly to the we're would said, six, by seven But a and information, about that, the you surprised timeline. comprehensive surprised in equation. a so extend get avoid to expectations then which package All that months, what we unless would And approval like typically have the certainly delivering be anybody's don't review going require and priority end. we're

Bob Labick

or this Analyst I Okay, be this talk I you about as submitting lot context, period? underlying finish Can exciting. And asking then may at this develop the a reactor. The markets close have from has time is thought submission the -- you in I you very you think mentioned on but getting originally figured during a you also So, about passed since to how opportunity was Day, line, and something exciting. time Netherlands touched your would of Obviously, that's set, the very which well. from just

competitive you are standpoint, the is from developed? So, to And market in? a supply situated how how fit

Rex Geveden

try Bob to do that. try I'll Yes, sure,

Moly are is Shine that there name -- are, We delivering we the is moved in kind than chain could a Shine value the that a other different own you So, delivering whatever in and commercialization; hear that our use cold offering. the are generator place up the kits offering of competitors Moly chain product. generic customer we for a are sense they're developing It's our with itself. the in that lot. a value

a we're So, in the different in value chain. little place

uranium. the others and the course, position, their ahead product into and cases but weapons-grade uranium Obviously, of and around already is they said are we're -- at -- their SA I from competitive And, some beginning players uranium based maintain think high that like established competitors of least, Lantheus they're that as our the Curium. low very enriched I've market. targets; no in

metal. Moly industrial uses Ours

stream. is because metal, we So, Since on very have have we non-proliferation waste nuclear reactor, commercial a ours limited continuity supply advantage. advantage. it Moly produced a ultimately, And industrial is then power

and that waste for proliferation of makes have advantages, advantages, strong. And offering. the very will cost and a quite of advantages, product all the that we compelling believe continuity advantages, risk supply for be uptake market we So,

Robb LeMasters

know, the that some the also core portfolio, there Day, portfolio. will. second is key therapeutics I then that. for that really you when add the Nordion when then portfolio, there the touch panned pretty of getting It's drug you kind really good opportunity [indiscernible] it almost might shares other includes and culminates of medical, across Rex quite And a that have on a really of we on really a exciting that opportunity therapeutics about think industry. exactly feel better. that I diagnostics as has those couple as lines, as put that know, stand better, the And out million manufacturing to the Nordion that and market the that area, still has Investor broader that of laid BWXT of said, for part $XXX opportunity opportunity the for it. business and out well our We the which general, exciting the as of we summarize in to said related we just That's as that we really you products outlook we those as you three relates out portfolio, aspects revenue, there, million contract, sort $XX have of business and sort years out markets, doing Rex has in gotten Overall, if in gotten statistics couple those other opportunities us. well see couple so product within a we core know, of as good thirdly, it and diagnostics three to EBITDA therapeutics, you and well growth a the

Bob Labick

much. you Thank so super. that's Okay,

Rex Geveden

Bob. welcome You're

Operator

this showing at [Operator questions no Instructions] further time. I'm

I will Kratz turn So, conference the any to Mark for over back remarks. closing

Mark Kratz

Thank call. you concludes for conference That this Thank us you, joining today. Andrea.

further can at have questions, at XXX-XXX-XXXX you If email reach investors@bwxt.com. by or phone me you

Operator

conference attending no The now you and Thank may has disconnect. presentation for today's concluded. you

BWX (BWXT) 23 Feb 222021 Q4 Earnings call transcript